Marcia P. Belvin
CytomX Therapeutics (United States) · 269 works · 12,999 citations · h-index 47
Top works
- A CONSERVED SIGNALING PATHWAY: The Drosophila Toll-Dorsal Pathway
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein
- Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome
- Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.
- Cactus protein degradation mediates Drosophila dorsal-ventral signaling.
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- A genome-wide analysis of immune responses in Drosophila
- Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- Dual Activation of the Drosophila Toll Pathway by Two Pattern Recognition Receptors
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
- Dual Detection of Fungal Infections in Drosophila via Recognition of Glucans and Sensing of Virulence Factors
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- A serpin mutant links Toll activation to melanization in the host defence of Drosophila
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- The Drosophila Immune Defense against Gram-Negative Infection Requires the Death Protein dFADD